Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS candidate RFK Jr told senators the GLP-1s are ‘miracle drugs’ but shouldn’t ...

Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinson’s disease. A phase 3 randomized controlled trial found no significant improvements with the GLP-1 exenatide in ...